Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944840 | 0.87 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6573763 | 0.87 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6574450 | 0.87 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7347413 | 0.87 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5307753 | 0.87 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731604 | 0.87 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731609 | 0.87 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6944834 | 0.87 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731238 | 0.87 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3000484 | 0.87 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337532-B1 | COMPOUND FOR CHELATING A METAL, RADIOPHARMACEUTICAL, MANUFACTURING PROCESS THEREFOR, AND DIAGNOSTIC KIT | SCHERING AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040043920-A1 | Compound for chelating a metal, radiopharmaceutical, manufacturing process therefor, and diagnostic kit | SCHERING AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337532-A2 | COMPOUND FOR CHELATING A METAL, RADIOPHARMACEUTICAL, MANUFACTURING PROCESS THEREFOR, AND DIAGNOSTIC KIT | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002044175-A2 | COMPOUND FOR CHELATING A METAL, RADIOPHARMACEUTICAL, MANUFACTURING PROCESS THEREFOR, AND DIAGNOSTIC KIT | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043920-A1 | Compound for chelating a metal, radiopharmaceutical, manufacturing process therefor, and diagnostic kit | MC5R, SLC30A5, SENP5 | SLC6A3 1182/4885SLC6A2 1485/4885SLC6A4 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.